Explore mots-c calculator-entry dose, vial-size, BAC-water and self-reported frequency distributions. Research context is separate from live observations.
Anonymized mots-c calculator entries are summarized by each chart's selected period. Frequency responses come from the separate vial-duration feature. Inputs are not verified administrations or unique people.
MOTS-c is a 16-amino-acid mitochondrial-derived peptide most often sourced for metabolic, exercise, and aging research. It ships as a lyophilized powder reconstituted with bacteriostatic water, and all evidence to date is pre-clinical.[1]
MOTS-c translocates to the nucleus under metabolic stress where it modulates expression of nuclear-encoded metabolic genes via AMPK activation, improves insulin sensitivity in skeletal muscle, and increases glucose uptake. It is one of a growing class of small mitochondrial-encoded peptides that signal between organelles.[2]
Mouse studies have shown improvements in age-related insulin resistance, diet-induced obesity, and exercise capacity.[3] No published Phase 2/3 human trials exist; MOTS-c remains a pre-clinical research peptide with active investigation into its role in metabolic aging and exercise mimetic activity.
Not FDA-approved for any indication. Research-grade material for in vitro / non-clinical use only.
MOTS-c has a reported half-life of ~4 hours. The pharmacokinetic reference models an interval of weekly; this is not a measured community cadence or a dosing recommendation. Short half-life relative to a weekly cadence means plasma MOTS-c clears almost entirely between doses. The downstream metabolic effects are thought to outlast the plasma half-life. Pharmacokinetic source: Lee et al. Cell Metab 2015 (MOTS-c discovery and PK). It is catalogued under Weight Loss on WPA.
14,911 MOTS-c reconstitution calculations have been logged by the WPA community.
This is the lifetime header population. Each chart and its associated analysis below use their own selected period and denominator; frequency responses are a separate cohort.
These figures come from anonymized WPA peptide calculator sessions, not verified administrations or unique people. Separate modal inputs do not establish a joint protocol. They are community input statistics — not dosing recommendations, and not medical advice.
WPA Analysis
MOTS-c is a 16-amino-acid peptide encoded by a small open reading frame within the 12S rRNA region of mitochondrial DNA — one of the founding members of the mitochondrial-derived peptide (MDP) family that the Pinchas Cohen group at USC characterized through the 2010s. Most DNA lives in the cell nucleus, but mitochondria — the energy factories inside every cell — carry their own small, separate strand of DNA, and MOTS-c is one of the peptides encoded there. The original molecular description came from Lee et al., Cell Metabolism 2015 ("The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance"), which showed that the peptide circulates in human plasma at age-declining levels, that it activates AMPK signaling in skeletal muscle — AMPK is essentially the body's master energy sensor, the switch that tells cells to burn fuel more efficiently — and that giving it to obese mice reduced adiposity (the amount of body fat stored in the body), restored insulin sensitivity, and improved glucose tolerance. The downstream Cohen-group work characterized MOTS-c as an exercise-mimetic: its plasma levels rise after exercise in humans, and giving it externally in mice produces some of the same metabolic benefits as physical training — without the actual training. Reynolds et al., Nature Communications 2021 ("MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis") extended that picture to age-related physical decline, and a small body of observational human work has linked higher endogenous MOTS-c levels to lower diabetes risk and a better cardiometabolic profile.
The critical caveat is that the human evidence base is essentially preclinical and observational — there is no published controlled clinical trial of synthetic MOTS-c administration in humans, no FDA-approved indication anywhere in the world, and no labeled dose, cadence, or administration route.
Research background is separate from the calculator observations below. Calculator entries do not establish administration, safety, effectiveness, or the reasons for an input.
WPA DOSING INSIGHT
The summaries use each chart's own period and, for frequency responses, its dose filter. Separate cohorts must not be combined into a protocol.
WPA RECONSTITUTION INSIGHT
Vial-size and BAC-water observations describe separate input distributions, not purchases or verified preparations. Separate modal inputs do not establish a joint protocol.
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.